Australia markets closed

Kuros Biosciences AG (CSBTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
1.92000.0000 (0.00%)
At close: 02:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9200
Open1.9200
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.9200 - 1.9200
52-week range1.9200 - 3.1000
Volume2,000
Avg. volume63
Market cap63.515M
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-0.2380
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

    Ad-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone paym

  • GlobeNewswire

    Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications

    Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market SCHLIEREN (ZURICH), Switzerland, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administrati

  • GlobeNewswire

    Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales

    Ad hoc announcement pursuant to Article 53 of the SIX listing rulesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update on its commercial activities. Direct sales of MagnetOs in the U.S. continued to accelerate in Q3 202